799 related articles for article (PubMed ID: 22325103)
1. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
2. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
4. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
6. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
7. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
8. Individualized targeted therapy for glioblastoma: fact or fiction?
Weller M; Stupp R; Hegi M; Wick W
Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers.
Singh N; Bal A; Aggarwal AN; Das A; Behera D
Future Oncol; 2010 May; 6(5):741-67. PubMed ID: 20465389
[TBL] [Abstract][Full Text] [Related]
10. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
11. Personalizing oncology: perspectives and prospects.
Mendelsohn J
J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
[TBL] [Abstract][Full Text] [Related]
12. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
13. Functional drug-gene interactions in lung cancer.
Smida M; Nijman SM
Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
[TBL] [Abstract][Full Text] [Related]
14. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
15. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
16. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.
Langer CJ
Crit Rev Oncol Hematol; 2012 Jul; 83(1):130-44. PubMed ID: 22280915
[TBL] [Abstract][Full Text] [Related]
17. Improving the outcomes: developing cancer therapeutics.
Utku N
Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
[TBL] [Abstract][Full Text] [Related]
18. Advances in treatment of lung cancer with targeted therapy.
Cagle PT; Chirieac LR
Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
[TBL] [Abstract][Full Text] [Related]
19. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Wiesweg M; Ting S; Reis H; Worm K; Kasper S; Tewes M; Welt A; Richly H; Meiler J; Bauer S; Hense J; Gauler TC; Köhler J; Eberhardt WE; Darwiche K; Freitag L; Stamatis G; Breitenbücher F; Wohlschlaeger J; Theegarten D; Derks C; Cortes-Incio D; Linden G; Skottky S; Lütkes P; Dechêne A; Paul A; Markus P; Schmid KW; Schuler M
Eur J Cancer; 2013 Oct; 49(15):3076-82. PubMed ID: 23876834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
